RA-9 manufacturers
- RA-9
-
- $45.00
-
2026-07-27
- CAS:919091-63-7
- Purity: 99.31%
- Supply Ability: 10g
|
| Product Name: | RA-9 | | Synonyms: | 4-Piperidinone, 3,5-bis[(4-nitrophenyl)methylene]-, (3E,5E)-;RA-9 UPS inhibitor;Unfolded,RA-9,cancer,RA 9,DUBs,Inhibitor,Apoptosis,Response,Deubiquitinase,cells,inhibit,Protein,ovarian,RA9,survival;RA-9, 10 mM in DMSO;(3E,5E)-3,5-Bis[(4-nitrophenyl)methylene]-4-piperidinone | | CAS: | 919091-63-7 | | MF: | C19H15N3O5 | | MW: | 365.34 | | EINECS: | | | Product Categories: | | | Mol File: | 919091-63-7.mol |  |
| Melting point | 230-233 °C(Solv: ethyl ether (60-29-7); acetonitrile (75-05-8)) | | Boiling point | 588.5±50.0 °C(Predicted) | | density | 1.414±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO: 4.17 mg/mL (11.41 mM; ultrasonic and warming and heat to 80°C) | | pka | 5.13±0.20(Predicted) | | form | Solid | | color | Light yellow to yellow | | InChI | 1S/C19H15N3O5/c23-19-15(9-13-1-5-17(6-2-13)21(24)25)11-20-12-16(19)10-14-3-7-18(8-4-14)22(26)27/h1-10,20H,11-12H2/b15-9+,16-10+ | | InChIKey | YUYPWAMLWZVHAE-KAVGSWPWSA-N | | SMILES | O=C(/C(CNC/1)=C/C2=CC=C([N+]([O-])=O)C=C2)C1=C\C3=CC=C([N+]([O-])=O)C=C3 |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Acute Tox. 4 Oral |
| Uses | RA-9 is a potent and selective proteasome-associated deubiquitinating enzymes (DUBs) inhibitor with favorable toxicity profile and anticancer activity. RA-9 blocks ubiquitin-dependent protein degradation without impacting 20S proteasome proteolytic activity. RA-9 selectively induces onset of apoptosis in ovarian cancer cell lines and primary cultures derived from donors. RA-9 induces endoplasmic reticulum (ER)-stress responses in ovarian cancer cells[1]. | | Biological Activity | RA-9 is a potent and selective inhibitor of cell-permeable proteasome-associated deubiquitinating enzymes (DUBs) with favorable toxicity and anticancer activity. It selectively induces apoptosis in ovarian cancer cell lines. | | in vivo | RA-9 (5 mg/kg; ip; one-day on, two-days off) inhibits human ovarian cancer cell growth in vivo and prolongs survival in a mouse model for ovarian cancer. < td class="col1 fwb"> Animal Model: | Six-week-old female immunodeficient (NCr nu/nu) mice | | Dosage: | 5 mg/kg | | Administration: | Ip; one-day on, two-days off | | Result: | Significant reduction in tumor burden at day 12. | | | target | | Target | Value | DUBs
() | | References | [1] Coughlin K, et al. Small-molecule RA-9 inhibits proteasome-associated DUBs and ovarian cancer in vitro and in vivo via exacerbating unfolded protein responses. Clin Cancer Res. 2014;20(12):3174-3186. DOI:10.1158/1078-0432.CCR-13-2658 |
| | RA-9 Preparation Products And Raw materials |
|
|
Tag:RA-9(919091-63-7)
Related Product Information
|
|
RA375
PI-1840
9H-Indeno[1,2-b]pyrazine-2,3-dicarbonitrile, 9-[(phenylmethoxy)imino]-
[1,2,4]Triazolo[1,5-a]pyrimidine-4(7H)-acetamide, N-[2-chloro-4-(trifluoromethyl)phenyl]-2-(3,6-dihydro-2H-pyran-4-yl)-5-ethyl-6-[4-[(5-hydroxy-6-methyl-4-pyrimidinyl)carbonyl]-1-piperazinyl]-7-oxo-
1H-Pyrazolo[3,4-d]pyrimidine, 6-(4-cyclopropyl-6-methoxy-5-pyrimidinyl)-1-[[4-[1-(1-methylethyl)-4-(trifluoromethyl)-1H-imidazol-2-yl]phenyl]methyl]-
Doxorubicin hydrochloride
|
According to the laws, regulations and policies related to "patent products", the sale of this product is prohibited!
ChemicalBook prompt
The patent owner or licensee of the product has not released any relevant information for the time being.
|